Straits Times Index
3,300.00 -4.00 (-0.12%) S&P 500
5,492.75 +5.72 (+0.10%) Dow
38,898.64 +63.78 (+0.16%) Nasdaq
17,873.50 +11.27 (+0.06%) Bitcoin USD
64,923.91 -4.89 (-0.01%) CMC Crypto 200
1,349.10 -33.57 (-2.43%)
Danaher Corporation (0R2B.L)
| Previous close | 257.51 |
| Open | 253.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 248.60 - 257.44 |
| 52-week range | 182.16 - 269.23 |
| Volume | |
| Avg. volume | 37,092 |
| Market cap | 178.755B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 0.29 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.
- PR Newswire
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.
- PR Newswire
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
